Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Change In Working Capital : $5.52 Mil (TTM As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is Skystar Bio-Pharmaceutical Co Change In Working Capital?

Skystar Bio-Pharmaceutical Co's change in working capital for the quarter that ended in Sep. 2014 was $-0.70 Mil.

Skystar Bio-Pharmaceutical Co's change in working capital for the fiscal year that ended in Dec. 2013 was $-17.85 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Skystar Bio-Pharmaceutical Co Change In Working Capital Historical Data

The historical data trend for Skystar Bio-Pharmaceutical Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skystar Bio-Pharmaceutical Co Change In Working Capital Chart

Skystar Bio-Pharmaceutical Co Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Change In Working Capital

Get a 7-Day Free Trial

-9.53

-8.73

-16.05

-1.99

-17.85

Skystar Bio-Pharmaceutical Co Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Change In Working Capital	Get a 7-Day Free Trial															-3.55	1.85	2.76	1.60	-0.70

Skystar Bio-Pharmaceutical Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.52 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Skystar Bio-Pharmaceutical Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Skystar Bio-Pharmaceutical Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Skystar Bio-Pharmaceutical Co (GREY:SKBI) » Definitions » Change In Working Capital

Traded in Other Exchanges

N/A

Address

No. 48 Keji Road, 4/F Building B, Chuangye Square, Gaoxin District, Xian, Shaanxi Province, CHN

Website

http://www.skystarbio-pharmaceutical.com

Skystar Bio-Pharmaceutical Co is a holding company. Through its subsidiaries, it is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products in the People's Republic of China. The company provides individually packaged animal wellness and pharmaceutical products for retail sale. It generates revenue from the sales of four product lines namely, veterinary medications, micro-organism, feed additives, and vaccines. The firm develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine; topicals, supplements, probiotics; diagnostic kits and animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets.

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Headlines

No Headlines